-
Lanstead Capital TR1
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS To download click here
-
FDA approves the Lupzuor™ PK study
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce that the US Food & Drug Administration (“FDA”) has approved the commencement of the pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™. The PK study is a Phase I study…
-
BOARD CHANGES
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides notification of changes to its Board of Directors. Over the last year, ImmuPharma has continued to progress Lupuzor™ toward its international Phase 3 trial in conjunction with its partner, Avion Pharmaceuticals. In addition, the Company has been active in repositioning…
-
BOARD APPOINTMENT
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce the appointment of Dr Tim Franklin, Chief Operating Officer, to the Board of Directors. Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer…
-
2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed. The results of each resolution were as follows: As at the date of the AGM, the number…
-
FDA to agree on the Lupzuor™ PK study via a written response to “Type
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that its US Lupuzor™ partner, Avion Pharmaceuticals (“Avion”) has received a positive response from the US Food & Drug Administration (“FDA”) for a “Type C” meeting. The FDA has advised that they do not require a formal face to face…
-
Notice of AGM and posting of Report & Accounts
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2020, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…
-
Director Retirement
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Dr Robert Zimmer, President & Chief Science Officer has confirmed to the Company that he will not be seeking re-election at the forthcoming Annual General Meeting scheduled for 28 June 2021 and will be retiring from ImmuPharma PLC and…
-
FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2020 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £5.9m (31 December 2019: £1.4m) –…
-
Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. As indicated in the 20 November 2020 announcement, Avion Pharmaceuticals (“Avion”), ImmuPharma’s licensing partner for Lupuzor™,…
